China Bevacizumab Industry Outlook to 2018

1
Investigation Report on China Bevacizumab Market,
2009-2018byChina Research and Intelligence

• Explore all reports for Life Sciences market
• _at_ http//www.chinamarketresearchreports.com/cat/li
  fe-sciences.html.

2
Investigation Report on China Bevacizumab Market,
2009-2018

• Bevacizumab is an important kind of remedy for
  metastatic colon cancer, which belongs to
  humanized anti-VEGF monoclonal antibody. Approved
  by FDA, bevacizumab came into the market in 2004,
  with the brand name of "Avastin". Its main
  mechanism is to inhibit the function of a natural
  protein called vascular endothelial growth factor
  (VEGF) that stimulates new blood vessel formation
  through specific binding so as to stop or delay
  growth of blood vessels in tumor, disconnect the
  delivery of oxygen and other nutrition necessary
  in tumor cells' growth, as well as to improve the
  effect of chemotherapy remedy. Public data shows
  that the global sales value of bevacizumab in
  2012 exceeded USD 6.3 billion, ranking the fourth
  among the 10 best selling monoclonal antibody
  drugs.
• Inquire for a discount on this report _at_
  http//www.chinamarketresearchreports.com/contacts
  /inquire-before-buy.php?name114724 .

3
Investigation Report on China Bevacizumab Market,
2009-2018

• As Chinese economy develops rapidly, Chinese
  people's lifestyle is changing tremendously. With
  the aging level increasing, environment pollution
  worsening, the incidence of cancer in China keeps
  rising. Statistics indicate that the annual
  increase of cancer patients in China takes up
  over 20 of the global, making China a capital
  antitumor remedy market of the world. Shanghai
  Roche Pharmaceuticals Ltd. declared on May 7,
  2010 that its bevacizumab injection (brand name
  "Avastin") was approved by the FDA for curing
  metastatic colorectal cancer. It is the official
  entry of the world's first angiogenesis inhibitor
  into Chinese market. The market investigation of
  CRI manifests that the sales value of Avastin in
  certain Chinese sample hospitals in 2010 was
  merely CNY 10 million, growing rapidly. It broke
  through CNY 200 million in 2013.
• Complete report available _at_ http//www.chinamarket
  researchreports.com/114724.html .